- Home
- MOLN vs IKT Comparison
MOLN vs IKT Comparison
Compare MOLN & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- IKT
- Stock Information
- Founded
- MOLN 2004
- IKT 2008
- Country
- MOLN Switzerland
- IKT United States
- Employees
- MOLN N/A
- IKT N/A
- Industry
- MOLN
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- IKT Health Care
- Exchange
- MOLN Nasdaq
- IKT Nasdaq
- Market Cap
- MOLN 142.6M
- IKT 140.5M
- IPO Year
- MOLN 2021
- IKT 2020
- Fundamental
- Price
- MOLN $3.72
- IKT $1.56
- Analyst Decision
- MOLN Hold
- IKT Buy
- Analyst Count
- MOLN 1
- IKT 2
- Target Price
- MOLN $4.00
- IKT $8.00
- AVG Volume (30 Days)
- MOLN 5.2K
- IKT 93.8K
- Earning Date
- MOLN 11-05-2025
- IKT 11-13-2025
- Dividend Yield
- MOLN N/A
- IKT N/A
- EPS Growth
- MOLN N/A
- IKT N/A
- EPS
- MOLN N/A
- IKT N/A
- Revenue
- MOLN $856,302.00
- IKT N/A
- Revenue This Year
- MOLN N/A
- IKT N/A
- Revenue Next Year
- MOLN $1,000.00
- IKT N/A
- P/E Ratio
- MOLN N/A
- IKT N/A
- Revenue Growth
- MOLN N/A
- IKT N/A
- 52 Week Low
- MOLN $3.36
- IKT $1.12
- 52 Week High
- MOLN $7.60
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- MOLN 50.93
- IKT 41.99
- Support Level
- MOLN $3.69
- IKT $1.50
- Resistance Level
- MOLN $3.85
- IKT $1.73
- Average True Range (ATR)
- MOLN 0.21
- IKT 0.10
- MACD
- MOLN 0.01
- IKT -0.02
- Stochastic Oscillator
- MOLN 14.29
- IKT 15.08
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.